Baird analyst Joel Beatty initiated coverage of Immutep (IMMP) with an Outperform rating and $7 price target. The firm believes lead agent eftilagimod alpha has “unique advantages” over Bristol-Myers’ (BMY) recently approved relatlimab and views Phase 2b NHSCC topline results due later in 2023 as “the next key catalyst,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMMP:
- Immutep receives CHMP advice on development of eftilagimod alpha
- Immutep to present overall survival data from TACTI-002 Phase II trial
- Immutep reports Q4 cash receipts $16K vs. $30K last quarter
- Immutep announces first patient enrolled, dosed in EFTISARC-NEO trial
- First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
